Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation ni hali ya ngozi inayojulikana kwa kuongezeka kwa rangi baada ya uvimbe wa ngozi. Inaweza kusababishwa na miale ya jua ya muda mrefu, uvimbe, au majeraha mengine ya ngozi, ikijumuisha yale yanayohusiana na chunusi. Watu wenye ngozi nyeusi kwa kawaida wana hatari kubwa ya kupata rangi nyekundu na kuathiriwa na jua kupita kiasi.
☆ Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) ni tatizo la ngozi la mara kwa mara ambalo hutokea baada ya ngozi kuvimba au kuumia. Inaelekea kudumu kwa muda mrefu na ni mbaya zaidi kwa watu wenye ngozi nyeusi (Fitzpatrick skin types III–VI). Ingawa mara nyingi hupungua mwenyewe, hii inaweza kuchukua muda, hivyo matibabu mara nyingi yanahitajika kwa muda mrefu. Kuchanganya matibabu tofauti hufanya kazi vizuri zaidi.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation ni matokeo ya kawaida ya uvimbe wa ngozi. Inaathiri zaidi watu wenye ngozi nyeusi, na mara nyingi. Uchunguzi unaonyesha kuwa hali kama postinflammatory hyperpigmentation ni mojawapo ya sababu kuu zinazowafanya watu wenye ngozi nyeusi kutafuta huduma za ngozi. Matibabu ya mapema ni muhimu katika kutatua postinflammatory hyperpigmentation, na kwa kawaida huanza na kudhibiti hali ya awali ya uvimbe. Mstari wa kwanza wa matibabu kwa kawaida huhusisha matumizi ya vijenzi vinavyoharisha ngozi pamoja na mafuta ya kujikinga na jua. Mawakala haya, kama hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts, yanaweza kupunguza upakaji wa rangi kupita kiasi. Zaidi ya hayo, retinoids, mequinol, ascorbic acid, niacinamide, N‑acetyl glucosamine, na soya pia hutumika kama mawakala wa kuondoa rangi, na matibabu mapya yanajitokeza. Ingawa matibabu ya kawaida kwa kawaida huwa na ufanisi mkubwa, taratibu (laser, chemical peel) zinaweza kuhitajika kwa visa vya ukaidi. Ni muhimu kutumia tahadhari katika matibabu haya ili kuepuka kuwashwa na kuongezeka kwa postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
